Achillion Pharmaceuticals Inc.

Mr. Kishbauch, who joined Achillion as President and Chief Executive Officer in July 2004, has had an impressive record of launching and commercializing products over his twenty years of pharmaceutical industry experience. Most recently, Mr. Kishbauch founded OraPharma, Inc., an emerging pharmaceutical company focused on oral health. In less than seven years, Mr. Kishbauch and his team completed clinical development and launched OraPharma's lead product, successfully took the Company public, and ultimately sold the Company to Johnson & Johnson in February 2003. Previously, Mr. Kishbauch spent several years as President and COO of MedImmune, Inc., a top-tier biotechnology company focused on infectious disease and cancer. Prior to that, he served as Vice President and senior product marketing executive for Ciba-Geigy where he oversaw the launches of two products, which at the time were the two most successful product launches in industry history as measured by first-year sales. Mr. Kishbauch began his career with The Procter and Gamble Company, received a B.A. in Biology from Wesleyan University, and an M.B.A. from the Wharton School of the University of Pennsylvania.

Mr. Truitt joined Lev from Johnson & Johnson, where he was Vice President of Sales and Operations and directed commercial operations and had P&L responsibility for sales, operations and national accounts at the company's OraPharma subsidiary. Mr. Truitt holds a B.S. degree in marketing from LaSalle University, Philadelphia, and an M.B.A. degree from St. Joseph's University, Philadelphia.

Jerome Birnbaum, Ph.D. is a pharmaceutical R&D Consultant and is a Co-founder of Achillion Pharmaceuticals, Inc., a development stage biotechnology company. Previously, Dr. Birnbaum was employed by Merck and Co., Inc. from 1966-1987 in various positions culminating as Vice President, Microbiology and Agricultural Research. From 1987 until his retirement in January 2000 he was employed in various positions by Bristol-Myers Squibb Company culminating as Senior Vice President, Strategic R&D Operations.

Robert L. Van Nostrand has served as a director since October 2006. He is currently Executive Vice President and Chief Financial Officer of AGI Dermatics, a bio-pharmaceutical laboratory specializing in skin photobiology. Previously, Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. for 21 years, most recently as the Senior Vice President and Chief Compliance Officer from 2005 until August 2007, and as the Vice President and Chief Financial Officer from 1996 through 2005. Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. (currently Deloitte and Touche). Mr. Van Nostrand serves on the board of directors of Apex Bioventures, Inc., a special purpose acquisition company focused in life sciences, and is Chairman of its audit committee, and he is on the board of Achillion Pharmaceuticals, Inc, a biotechnology company focused on infectious disease, and is Chairman of its audit committee. Mr. Van Nostrand received a B.S. in Accounting from Long Island University, New York, and completed advanced management studies at the Wharton School. Mr. Van Nostrand is a Certified Public Accountant. Stock transaction information provided by EDGAR Online. Metabolix, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Mr. White is Chief of Staff and Chief Administrative Officer of Cowen and Company. Previously, Mr. White was a member of SG Capital Partners, the Merchant Banking Division of Cowen, which he joined in 2003. Prior to joining the Merchant Banking Division, Mr. White was a member of the Equity Capital Markets Group of Cowen where he covered the technology and consumer sectors. Prior to this, Mr. White worked at Salomon Smith Barney in the Equity Capital Markets Group. In addition, Mr. White has seven years experience as a practicing securities and M&A lawyer at Brown Rudnick Freed & Gesmer and Lord Day & Lord, Barrett Smith. Mr. White received his B.A. from Amherst College and his J.D. from the University of Michigan Law School.

Mr. Wright joined PharmAthene as President and Chief Executive Officer in July 2003. Prior to joining PharmAthene, Inc. he served as President and Chief Operating Officer of GenVec Inc, and previously President and Chief Business Officer of Guilford Pharmaceuticals. Mr. Wright served as Executive Vice president for MedImmune, Inc. from 1990 to 2000 where he was responsible for building MedImmune's commercial operation and growing product sales from $0 to over $400 million per year. Additionally he has held various marketing and sales positions at pharmaceutical companies including Smith-Kline & French, G.D. Searle, and Glaxo. Mr. Wright received his Master of Arts in Speech Pathology and Audiology from the University of South Florida.

Mr. Scheer, President of Scheer & Company, Inc., has 25 years of experience in the life sciences with activities in venture capital, corporate strategy, and transactional advisory services. In venture capital, Mr. Scheer has been involved in the founding and has been a member of the Boards of Directors of ViroPharma, Inc., OraPharma, Inc.,(now a unit of Johnson & Johnson), Esperion Therapeutics, Inc., (of which he was Chairman, and now a unit of Pfizer, Inc.), Sopherion Therapeutics, Inc (of which he was Chairman), Tengion, Inc. (of which he is Chairman), and Aegerion Pharmaceuticals (of which he is Chairman). He has led engagement teams from Scheer providing corporate strategic advisory services to a broad range of publicly- and privately-held companies. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He is also a member of the Advisory Board to the Harvard Malaria Initiative and of the Leadership Council for the Harvard School of Public Health. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.

Dennis Liotta has discovered crucial HIV-fighting drugs, founded several drug discovery companies, and been recognized as a seminal contributor to medicinal chemistry. Along with two Emory University colleagues, Dr. Liotta discovered (lamivudine) 3TC and (emtricitabine) FTC, part of the anti-HIV "cocktail" taken by 80 percent of HIV-positive patients in the United States, with annual sales of more than $1 billion. Dr. Liotta was a co-founder of Pharmasset Inc., a pharmaceutical company in Atlanta that has developed two additional anti-HIV drugs to help patients for whom a standard cocktail treatment has lost effectiveness. The company has been successful not only in drug discovery but in its financial backing, having become one of the biggest capital fund raisers among biotechnology companies in the Southeast. In 1995, Dr. Liotta was an important early contributor to Triangle Pharmaceuticals in North Carolina, which developed anti-AIDS compounds. In 2002, Gilead Sciences bought the company for $464 million. Dr. Liotta serves as an advisor or consultant for several major pharmaceutical companies. He holds numerous patents on anti-viral and anti-cancer agents, has received many academic and professional honors and awards, and has published more than 200 peer-reviewed articles. A professor of chemistry and former vice president for research at Emory University, Dr. Liotta earned his bachelor's degree at Queens College and his doctorate at the City University of New York.

Jean-Francois Formela, M.D., is a Senior Partner in the life sciences sector for Atlas Venture, a venture capital firm, and has served as a member of our board of directors since June 1999. Prior to joining Atlas Venture in 1993, Dr. Formela was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough Corporation in the United States. During his tenure at Schering-Plough, he was responsible for the marketing of Intron A, Schering-Plough s alpha-interferon. In his last position at Schering-Plough, he directed the U.S. Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Dr. Formela practiced emergency medicine at Necker University hospital in Paris. Since joining Atlas Venture, he has been involved in the formation of companies such as ArQule, Inc., MorphoSys, Exelixis, Inc., deCODE genetics, Inc., Nuvelo, Inc., Cellzome AG, Archemix Corp. and Aureon Biosciences Corporation. Dr. Formela currently serves as a director of Achillion Pharmaceuticals, Inc., Arca Discovery, Inc. Cellzome Inc., Compound Therapeutics, NxStage Medical, Inc. and Resolvyx Pharmaceuticals, Inc. He holds an M.D. degree from the Paris University School of Medicine and an M.B.A. from Columbia University.

Mike has 30 years of experience in the biopharmaceutical industry and is currently President and CEO of SGX Pharmaceuticals (formerly Structural GenomiX). Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, a subsidiary of BioChem Pharma, from 1994 to 1998. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President, Corporate Development, and Director, International Licensing. Mike currently serves on the board of directors of Achillion Pharmaceuticals and IDM Pharma (formerly known as Epimmune).

Mr. Simon has served as a member of our board of directors since June 2002. In February 2005, Mr. Simon co-founded Clarus Ventures, LLC, a venture capital firm focused on life sciences companies. Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company. Mr. Simon served in various management positions at Genentech, Inc., including its vice president of business and corporate development. Mr. Simon is currently on the board of directors of Sientra, Inc., and several pharmaceutical companies: Barrier Therapeutics, Inc., Neosil, Inc., QuatRx Pharmaceuticals Company, Pearl Therapeutics, Inc., Poniard Pharmaceuticals, Inc., and Verus Pharmaceuticals, Inc. He is also on the advisory council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a bachelor of sciences degree in microbiology from the University of Maryland and a masters in business administration in marketing from Loyola College.

In August 2008, Dr. Ryser joined Telik as Senior Vice President, Corporate Strategy. Prior to joining Telik, Dr. Ryser most recently served as founding and managing partner of Bear Stearns Health Innoventures, a $212 million private equity fund established in 2000. He also founded and managed, beginning in 1998, International Biomedicine Management Partners, a biotechnology venture fund. Previously, Dr. Ryser held various senior management positions of increasing responsibility at F. Hoffmann-La Roche, including Scientific Assistant to the President, Global Research and Development. Dr. Ryser has served on numerous boards of directors in both public and private biotechnology companies. Dr. Ryser received a Ph.D. degree in molecular biology from the University of Basel.

Mr. Van Nostrand currently serves as the Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc. He formerly held positions as both Chief Compliance Officer and Chief Financial Officer of OSI Pharmaceuticals. He has served as a director of Achillion since April 2007.